TABLE 1.
Protection induced by immunization with PyMSP-1 and PyMSP-8 recombinant antigensa
| Antigen | Dose (μg/immunization)b | % Parasitemia on day 8 | Survival (no. of surviving mice/ total no. of mice)c |
|---|---|---|---|
| rPyMSP-8 | 1 | 16.9 ± 16.0d | 3/5e |
| 5 | 5.6 ± 3.3d | 5/5e | |
| 10 | 2.1 ± 2.2d | 9/10e | |
| 25 | 4.6 ± 3.1d | 5/5e | |
| GST-PyMSP-8C | 10 | 52.4 ± 17.9 | 0/14 |
| 25 | 47.9 ± 17.4 | 0/5 | |
| 50 | 39.6 ± 4.0 | 0/5 | |
| rPyMSP-142 | 1 | 25.0 ± 23.4d | 0/5 |
| 5 | 26.9 ± 22.3d | 1/5 | |
| 10 | 40.6 ± 18.5 | 1/9 | |
| 25 | 29.0 ± 20.8d | 3/10e | |
| GST-PyMSP-119 | 10 | 24.0 ± 23.1d | 6/15e |
| 25 | 8.5 ± 10.9d | 2/4e | |
| GST control | 10 | 64.5 ± 17.8 | 0/5 |
| 25 | 52.2 ± 15.1 | 0/5 | |
| 50 | 46.0 ± 22.5 | 0/4 | |
| Quil A control | 47.7 ± 16.8 | 0/28 |
a
Data compiled from six immunization and challenge experiments (four to five mice/group/experiment).
b
All animals were immunized three times at 21-day intervals with the indicated amount of each recombinant antigen formulated with Quil A as an adjuvant (25 μg/dose).
c
Clearance of P. yoelii 17XL blood-stage parasites, with maximum parasitemia not exceeding 50% in any animal.
d
Significantly reduced compared to Quil A controls (analysis of variance, P < 0.05).
e
Significantly different compared to Quil A controls, considering survival period and percent mortality (Mantel-Haenszel log rank test, P < 0.05).